Skip to main content
Nobel Prize 2025 in Physiology or Medicine
© The Nobel Committee for Physiology or Medicine. Ill. Mattias Karlén

News categories: Honors & Funding

They discovered how the immune system is kept in check

This years Nobel Prize in Physiology or Medicine has been awarded in the field of Immunology. As ImmunoSensation, we sincerely congratulate the laureates.

The body’s powerful immune system must be regulated, or it may attack our own organs. Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi are awarded the Nobel Prize in Physiology or Medicine 2025 for their groundbreaking discoveries concerning peripheral immune tolerance that prevents the immune system from harming the body.

Every day, our immune system protects us from thousands of different microbes trying to invade our bodies. These all have different appearances, and many have developed similarities with human cells as a form of camouflage. So how does the immune system determine what it should attack and what it should defend?

Mary Brunkow, Fred Ramsdell and Shimon Sakaguchi are awarded the Nobel Prize in Physiology or Medicine 2025 for their fundamental discoveries relating to peripheral immune tolerance. The laureates identified the immune system’s security guards, regulatory T cells, which prevent immune cells from attacking our own body.

“Their discoveries have been decisive for our understanding of how the immune system functions and why we do not all develop serious autoimmune diseases,” says Olle Kämpe, chair of the Nobel Committee.

Shimon Sakaguchi was swimming against the tide in 1995, when he made the first key discovery. At the time, many researchers were convinced that immune tolerance only developed due to potentially harmful immune cells being eliminated in the thymus, through a process called central tolerance. Sakaguchi showed that the immune system is more complex and discovered a previously unknown class of immune cells, which protect the body from autoimmune diseases.

Mary Brunkow and Fred Ramsdell made the other key discovery in 2001, when they presented the explanation for why a specific mouse strain was particularly vulnerable to autoimmune diseases. They had discovered that the mice have a mutation in a gene that they named Foxp3. They also showed that mutations in the human equivalent of this gene cause a serious autoimmune disease, IPEX.

Two years after this, Shimon Sakaguchi was able to link these discoveries. He proved that the Foxp3 gene governs the development of the cells he identified in 1995. These cells, now known as regulatory T cells, monitor other immune cells and ensure that our immune system tolerates our own tissues.

The laureates’ discoveries launched the field of peripheral tolerance, spurring the development of medical treatments for cancer and autoimmune diseases. This may also lead to more successful transplantations. Several of these treatments are now undergoing clinical trials.

This article was originally published on nobelprize.org.

 

Related news

Gut

News categories: Honors & Funding

Millions in funding for the new MikrobiomProCheck research project

The human gut microbiome is as unique as a fingerprint. It plays a central role in chronic inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis. Yet its potential for diagnostics and personalized therapy for patients remains untapped. The MikrobiomProCheck research project aims to change this. To this end, the Leibniz Institute for Analytical Sciences (ISAS), the Universities of Bonn, Bielefeld, and Duisburg-Essen, Biofidus AG, and Lead Discovery Center GmbH are receiving approximately 3.4 million euros from the state government of NRW and the European Union.
View entry
Zwei Personen: Links Prof. Pröpstl und rechts Prof. Boztug

News categories: Honors & Funding

University of Bonn and University Hospital Bonn strengthen early-career clinical scientists

The Faculty of Medicine at the University of Bonn and the University Hospital Bonn (UKB) are jointly launching the EKFS doctoral program IMMUNE PILOT, which introduces medical students to clinical-scientific research at an early stage. The structured program is positioned at the interface of immunology, neuroscience, and genetics and is aimed at students with a strong interest in research who aspire to pursue a career as clinician scientists. The program is funded by the Else Kröner-Fresenius Foundation (EKFS).
View entry
PrepAIred

News categories: Honors & Funding

Precise active ingredients against pancreatic cancer

Pancreatic cancer remains one of the deadliest forms of cancer. At the German Cancer Congress 2026, German Cancer Aid is now presenting three large-scale projects that it is funding as part of its “German Alliance for Pancreatic Cancer” funding priority. In the funded project PrepAIred, Bonn researchers , in cooperation with the University of North Carolina (USA), want to use AI-based protein design to specifically combat pancreatic cancer. German Cancer Aid is funding the project with a total of 1.99 million euros over a period of four years.
View entry

Back to the news overview